whatever I need, it needs to be mounted and recorded to the camera (and XLR is heavily preferred).
So red sells an expander module for just under $5000 and Teradeck has one for $2700. How drastic is the sound quality difference between these and mountable preamp like the beachtek or saramonic ($150)? Or if sound quality is not the issue, what is?

Hello all,
I have a simulation to run at varying Knudsen numbers.
I have used the wedge15Ma5 tutorial file as a starting point and managed to get it to run with a modified geometry and mesh. I have selected a Mach number of 5 for my simulations and wanted to modify the Reynolds number to achieve Knudsen numbers of 0.1, 1 and 10.
I do not understand however how to vary the density in the simulation. I tried modifying the number of particles in the dsmcProperties dictionary, but that only seemed to change the stability of the simulation.
Could somebody indicate me the correct way to do this?
Thanks in advance.

Seemingly-Harmless made a request that I put together that what I might know about the Clinical Hold.
So, I didn't want to wait until I had the time; Rather, I do this right now and put what ever I have down and if anyone else knows more, please add to this by commenting and adding that information there in the comment sections.
Some of the questions seemingly-harmless would like answered are:
my understanding is the clinical hold happened as the data was bad/incomplete/unformatted coming from amarex.- what was the main reason for the hold?- did cytodyn initiate the hold voluntarily or did the FDA impose it?- was this due to brazil data or cd10/12 data?- what is the average time for a clinical hold? - has this been unreasonably long?- what are the metrics for us to have it lifted?- is the clinical hold reasonable?- was it because of 2 deaths in the trial?- for what indications is the hold for - HIV and covid right?- why would the FDA have a hold for some indications and not others?- will the hold cause trial validity to be erased so we have to start over?- will resolution of the hold also mean clarity/validity of trial data?- are there any long lasting problems to be expected from this?- or is it merely a pause and nothing to worry about once it is lifted?
So, Seemingly-Harmless, I'll post links and excerpts which should answer many of these, but it will be in random order and the answers will have to be found in the context of the material.
Everyone else, please try to answer the questions above in the comments below if you know the answers.
---
https://www.cytodyn.com/newsroom/press-releases/detail/598/cytodyn-announces-partial-clinical-hold-of-hiv-program-and
​
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the United States. Further, the Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission.
The Company was not enrolling any new patients in the trials placed on hold in the United States. The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved. CytoDyn intends to work closely with the FDA to resolve the partial clinical hold as soon as possible. Under the full clinical hold on the COVID-19 program, no new clinical studies may be initiated until the clinical hold is resolved. The Company is not currently conducting any COVID-19 trials in the United States, as it is evaluating the most optimal programs on which to focus its resources and attention.
“CytoDyn is committed to FDA compliance,” said Scott A. Kelly, M.D., Chief Medical Officer of CytoDyn. “We are evaluating our clinical programs and are working to resolve the issues underlying the clinical holds as soon as possible in close communication with the FDA. We will provide an update when we have additional information.”
The Company will host a webcast conference call to discuss this announcement and other updates on March 31, 2022 at 5:30 AM (PT) and 8:30 AM (ET). Connection details are provided below:
Date:Thursday, March 31, 2022 Time:5:30 AM PT / 8:30 AM ETAccess:Questions:https://services.choruscall.com/mediaframe/webcast.html?webcastid=v9IRoWUqPrior to the webcast, questions can be submitted online to [[email protected]](mailto:[email protected])
---
Conference Call 3/31/22
https://www.reddit.com/LeronLimab_Times/comments/tus870/transcription_of_conference_call_33122/?utm_source=share&utm_medium=web2x&context=3
​
"Scott Kelly 9:00: 2 cardiac events led to pausing CD16. they don't know if these patients are LL or placebo. They want to pause the trial b/c our experience w/LL was in healthy volunteers and not in critically ill Covid 19 population of sick individuals. They have a preplanned DSMC meeting data safety monitoring committee in early April for both studies. So upon clearance of the DSMC we plan on removing the pause. We are in communication with ANVISA and the FDA and reported the events to each agency, but this was CytoDyn's decision. Full clinical hold on US IND Covid 19, and partial clinical hold for IND for HIV. The FDA wants aggregated safety data across all indications as our prior CRO was not aggregating safety data. We will correct this. We believe this is a solvable problem. We have contracted with a new pharmaco-vigilance CRO to move forward. So we expect about an 8-12 week, (June-July 2022), timeline and seek advice from the FDA."
---
Conference Call 6/30/22
https://www.reddit.com/LeronLimab_Times/comments/voy428/conference_call_63022_antonio_migliarese/?utm_source=share&utm_medium=web2x&context=3
Antonio Migliarese: We have been addressing and drafting the clinical holds for HIV and Covid 19 and strengthening our clinical operations and prioritizing patient safety. We have strong project team in place and will provide an update in progress towards in addressing clinical hold and provide an update on the pause on Covid 19 Brazilian trials.
18:05 Scott Kelly: Thank you Antonio. So, I would like to begin by addressing the partial clinical hold on our HIV program & clinical hold on our Covid 19 program. To provide project management timelines for submitting the necessary materials in September of this year. Our initial time frame of 8-12 weeks, was dependent on us being provided data from former CRO according to industry standards. In the process of analyzing the data, in conjunction with our pharmacovigilance experts, we realized we needed to convert the data into industry standard format. To be clear, We have the data. It is really a data conversion issue. Unforeseen data quality and other data related issues remain a risk that could impact the time line. AM, do you want to add some color on this?
18:50 Antonio Migliarese: Thanks Scott. One of the things we want to highlight is that addressing the clinical hold is our number one priority in the organization and this is an all hands on deck effort. As we mentioned earlier, we have a strong project team in place, which is led internally, by our chief top performers, who have vast industry experience including an internal project manager. This is led by our senior director of clinical operations, Joe Meidling and our vp of project management, Bernie Cunningham. We've additionally engaged in CRO, clinical research organization that has deep experience in root sources in the areas of pharmacovigilance, safety data based management analysis. We also have the regulatory consulting firm that is assisting us with the preparation and review of the various regulatory communication, and lastly we have the data to work with an overall regulatory strategy advising group. This group is one of the most reputable at being regulatory consulting firms led by former FDA regulators.
To provide a little more color on our project management, this team has a line by line detailed project plan with paths, timelines and milestones where its various team members are accountable. Our team holds a series of meetings designed to check in, discuss, progress for milestones, roadblocks and risks to the critical paths. These meetings occurs at various intervals throughout the week and the month. This allows us to identify issues as quickly as possible to trouble shoot and identify ways to overcome and impact on overall timeline. Furthermore, this allows us to identify opportunities to bring in additional resources and where if possible to expedite time.
https://www.reddit.com/LeronLimab_Times/comments/vpg34v/63022_conference_call_scott_kelly_and_chris/?utm_source=share&utm_medium=web2x&context=3
​
20:33 Scott Kelly: Thanks Antonio. I will address the pausing for Covid19 Brazil trial. In consideration to potentially un-blind the data. The trials in brazil were never put on clinical hold. CytoDyn's clinical team decided to pause the Covid 19 trials in Brazil, as the Data Safety Monitoring Board DSMV, had a scheduled predetermined date to evaluate safety within a few weeks. The DSMB evaluated the safety portion only of the trial, not the efficacy, but the recommendation was to continue the trial with ongoing monitoring, and in term analysis according to the trial protocol. We are currently awaiting to hear from ANVISA. As we wait for approval to proceed with the trial, we will continue to analyze the dynamics of the Covid 19 landscape as it unfolds with a particular emphasis on the critical Covid 19 population. In regard to the potential to un-blinding of the data, we have had many people request the potential to un-blind the data early. We are considering all options and are working with our team, including our own statisticians, our Einstein clinical team in in Brazil, Einstein statisticians as well as our partner BIOMME.
The updates on our clinical programs regarding HIV BLA, there has been some concerns that we are abandoning the BLA for HIV and to be clear, we are not abandoning the HIV BLA. We are currently working to achieve the deliverables required by the FDA to lift the clinical hold. We have requested a type c meeting with the FDA to gain further guidance with respect to completion of the BLA. Once we achieve the lift on clinical hold and receive further clarities from our type c meeting request from the FDA, we will be in better position to provide an updated timeline analysis.
​
https://www.reddit.com/LeronLimab_Times/comments/vpt3cg/63022_conference_call_question_and_answe?utm_source=share&utm_medium=web2x&context=3
​
46:13 Christine: Why are we extended use of HIV LRM patients terminated by the FDA and forced to find another treatment? When reportedly, LRM was keeping them alive and many in remission and did Charlie Sheen find new medications?
Scott Kelly: So it was required by FDA due to the partial clinical hold of HIV as other treatment options were available for these patients and I can't comment on Charlie Sheen.
---
https://clinicalinfo.hiv.gov/en/drugs/leronlimab/patient
​

Select clinical trials of leronlimab

On March 30, 2022, the developer’s of leronlimab announced that the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on the company’s HIV program. The partial clinical hold affects participants who are enrolled in extension trials; participants in these trials will switch to other available treatment. Until the partial clinical hold is lifted, no clinical studies will be initiated or resumed. For more information about the clinical hold, please refer to the drug developer’s March 30, 2022 press release.7
Study Name: NCT00642707Phase: 2aStatus: This study has been completed.Location: United StatesPurpose: The purpose of this study was to look at the effectiveness, safety, and drug properties of different doses of leronlimab and compare leronlimab to a placebo. Leronlimab was given as monotherapy and by subcutaneous infusion.8,9Selected Study Results: Results published in The Journal of Infectious Diseases (2010) showed that leronlimab had substantial and prolonged activity against HIV. The level of antiviral reponse increased as the total amount of leronlimab administered over the treatment period increased. The greatest antiviral effect was seen with leronlimab 324 mg weekly, producing an average maximum reduction in viral load of 1.65 log10 copies/mL.9
Study Names: (1) PRO 140_CD 01; NCT02175680 and (2) PRO 140_CD 01-Extension; NCT02355184Phase: 2bStatus: PRO 140_CD 01 has been completed. The leronlimab HIV program was placed on partial clinical hold. Please refer to the ClinicalTrials.gov record and/or the drug developer’s website for updates on the status of PRO 140_CD 01-Extension.Location: United StatesPurpose: The purpose of the PRO 140_CD 01 study was to evaluate the safety and efficacy of leronlimab monotherapy for the maintenance of viral suppression in participants who had undetectable viral load levels on ART. The PRO 140_CD 01-Extension study is evaluating the long-term effectiveness and safety of leronlimab monotherapy for HIV treatment.6,7,10,11Selected Study Results: Results published in HIV Clinical Trials (2018) showed that in the CD01 study, 23 out of 41 participants (56.1%) maintained viral suppression throughout the 12 week monotherapy treatment phase. Eighteen participants did not maintain suppression during the treatment phase, with a mean time to viral rebound of 51.3 days since the initiation of leronlimab monotherapy. In the CD01 Extension study, five out of 16 participants experienced viral rebound, with a mean time to rebound of 323 days.6
Study Names: (1) PRO 140_CD 02; NCT02483078 and (2) PRO 140_CD 02 Extension; NCT02990858 and (3) PRO 140_CD02_OpenLabel; NCT03902522Phase: 2b/3Status: PRO 140_CD 02 has been completed. The leronlimab HIV program was placed on partial clinical hold. Please refer to the ClinicalTrials.gov record and/or the drug developer’s website for updates on the status of PRO 140_CD 02 Extension and PRO 140_CD02_OpenLabel.Location: United States and Puerto RicoPurpose: The purpose of the PRO 140_CD 02 study was to look at the safety and effectiveness of using leronlimab with a failing ART regimen for 1 week and then using leronlimab with an optimized ART regimen for 24 weeks. PRO 140_CD 02 Extension is designed to provide eligible participants with continued access to leronlimab. PRO 140_CD02_OpenLabel is a single-arm open-label trial.7,12–14Selected Study Results: Results from the CD 02 trial presented at ASM Microbe 2019 showed that 64% of participants who received a single subcutaenous dose of leronlimab had a significant reduction in viral load levels from baseline after 1 week, as compared to 23% of participants who received placebo.15
Study Names: PRO 140_CD03; NCT02859961 and (2) PRO 140_CD03 Extension; NCT05271370Phase: 2b/3Status: The leronlimab HIV program was placed on partial clinical hold. Please refer to the ClinicalTrials.gov record and/or the drug developer’s website for updates on the status of PRO 140_CD03 and PRO 140_CD03 Extension.Location: United StatesPurpose: The purpose of the PRO 140_CD03 study is to evaluate the safety and effectiveness of leronlimab monotherapy for the maintenance of viral suppression in participants who had undetectable viral load levels on ART. The PRO 140_CD03 Extension study is evaluating the long-term safety and effectiveness of leronlimab monotherapy.4,7,16Selected Study Results: Preliminary results presented at CROI 2019 indicated that the majority of participants who received higher weekly subcutaneous doses of leronlimab (525 mg and 700 mg) were able to maintain viral suppression.17
For more details on the studies listed above, see the Health Professional version of this drug summary.
What side effects might leronlimab cause?What side effects might leronlimab cause?

What side effects might leronlimab cause?

One goal of HIV research is to identify new drugs that have fewer side effects. The following side effects were observed in some of the studies of leronlimab listed above.
NCT00642707:
In this Phase 2a study, the most common side effects that were associated with either placebo or leronlimab included the following: diarrhea, headache, swollen lymph nodes, and high blood pressure. Side effects occurring at or around the injection site were mild and temporary and included hardening of the tissue, pain, and irritation.9
PRO140_CD 01 (NCT02175680) and PRO 140_CD 01-Extension (NCT02355184):
Safety data from 41 participants in the CD_01 study and 16 participants in the CD_01-Extension study found no serious side effects related to leronlimab treatment or study discontinuations due to a side effect. In both studies, mild and temporary local injection site reactions accounted for all of the side effects that were related to the study drug.6,10,11
PRO 140_CD 02 (NCT02483078); PRO 140_CD 02 Extension (NCT02990858):
In the CD_02 study, 52 participants were randomly assigned to either the leronlimab or placebo group. Final results from the study showed that 65.4% of participants experienced at least one side effect and 19.23% of participants had at least one treatment-related side effect. One participant discontinued treatment because of a side effect. No treatment-related serious side effects were reported. Injection site reactions that occurred during the study were mostly mild and went away on their own. Forty participants have enrolled into the CD_02 Extension study.12,13,15
PRO 140_CD03 (NCT02859961):
In the ongoing CD03 trial of leronlimab monotherapy, preliminary data was presented on 226 participants in the 350-mg dose group, 115 participants in the 525-mg dose group, and 43 participants in the 700-mg dose group. Thus far, the incidence and severity of side effects have not increased with the dose. Most side effects were mild in intensity and no side effect pattern was observed. None of the serious side effects that occurred were related to leronlimab. The majority of injection site reactions were mild and went away on their own.4,17
Because leronlimab is still being studied, information on possible side effects of the drug is not complete. As testing of leronlimab continues, additional information on possible side effects will be gathered.
​
---
https://stocktwits.com/Cytomight/message/483658418
The partial hold is on what group? Extension arm? Is that monotherapy group? Is combo group still going? Who is paying for combo therapy trials?
​
https://investorshangout.com/post/view?id=6467676#ixzz7eLl6kBek
This is what we know, sfaik:
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the United States. Further, the Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission.
The Company was not enrolling any new patients in the trials placed on hold in the United States. The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved. CytoDyn intends to work closely with the FDA to resolve the partial clinical hold as soon as possible. Under the full clinical hold on the COVID-19 program, no new clinical studies may be initiated until the clinical hold is resolved. The Company is not currently conducting any COVID-19 trials in the United States, as it is evaluating the most optimal programs on which to focus its resources and attention.
https://stocktwits.com/ohm20/message/483798090
According to Cytodyn the partial hold shut down the extension trials. Which makes absolutely no sense. A partial hold will close off a certain trial protocol or parts of a protocol but not others. The only protocols active are the extensions if those are shut down then it is a complete hold.
---

21:19 Scott Kelly: Thank you Cyrus. Before I begin introducing the new Scientific Advisory Board Members, I want to address a current question I received from investors regarding our new leadership. You know when we first began our search for our new CEO, the BODs at CytoDyn was focused on finding a unique individual with experience in corporate strategy in development of capital markets, licensing agreements, corporate governance with a firm scientific background and the ability to be a strategic thinker. We needed someone who not only would understand the potential of leronlimab, but would execute on those opportunities. We believe we have found that person in Dr. Arman. I work with Dr. Arman on a daily basis. He is an analytical and methodical thinker. He is focused and he works tirelessly. He has a unique ability to understand the science, but can switch on a moments notice to evaluate the business principles to support further advancement of an idea into a clear clinical path forward. He has chosen leronlimab after much due diligence. We believe leronlimab is now in the best of hands. One of the things that Dr. Arman and I agree on wholeheartedly, is to focus and surround ourselves with people that we believe will make leronlimab a success with our current focus and initiatives. Under the leadership of Dr. Arman, I can tell you, we believe our team has never been stronger, and the work we are currently doing is placing CytoDyn and leronlimab on the best potential path for success.
22: 50: As Dr. Arman mentioned, we do believe that leronlimab's role in HIV-NASH is a unique opportunity. We have the potential to assist with controlling the viral load, while possibly helping to reduce steatosis and fibrosis. NASH is a complex disease. But it is even more complex in the HIV population. People living with HIV may have multiple comorbidities. HIV virus may directly cause inflammation and fibrosis, while hepatotoxicity is associated with antiviral agent / aging and steatosis. In addition, HIV causes leakiness in the gut barrier, resulting in increased levels of endotoxin reaching the liver through the portal circulation. There is evidence that HIV itself may even bind with hepatocytes via the CCR5 receptor and trigger down stream cytokine responses that are both pro-inflammatory and pro-fibrotic in nature. And people living with HIV, the rate of NAFLD is approximately 50% and the the NASH rates are almost double the general population. Due to the underlying diagnosis of HIV, most of these patients are excluded from clinical trials for NASH, and this represents an unmet medical need.
24:00: So now I would like to introduce you to the newest members of our Scientific Advisory Board that Dr. Arman had mentioned. We are very proud of this. Dr. Stephan Gluk is the former vice president of global medical affairs at Celgene corporation since October 2014 until its acquisition by Bristol Meyer Squibb for $74 Million in 2019. He then served as the VP and the head of Oncology for Regeneron from 3/2020 - 3/2022 . Prior to Celgene, he was Professor at department of medicine at University of Miami in Florida. As VP of Global Medical Affairs at Celgene, he over saw breast, ovarian, bladder cancer activities worldwide, for the Celgene corporation as well as the Immunow Oncology program. He has been the principle investigator for 37 clinical studies in breast cancer. He has authored or co-authored over 250 articles. In addition, Dr. Gluk has written or cowritten a number of book chapters and numerous journal abstracts. He has presented more than 350 papers at national and international meetings. He will be assisting us in identifying partnership opportunities, trial designs, identifying collaborations, and solid tumor opportunities.
25:19 I would now like to introduce you to Dr. Naoto Ueno Dr. Ueno has a strong background in translational breast cancer research in the area of cancer biology and molecular therapeutics. He trained as a medical oncologist at MD Anderson, simultaneously learned how to conduct clinical research and perform data analysis related to breast cancer and ovarian cancer. He is now a practicing physician who has experience in conducting both targeted and gene therapy clinical trials. He has a strong interest in mTNBC, inflammatory breast cancer, metastasis, cancer stem cells and drug resistance of cancer cells. He will be assisting CytoDyn with trial design and identifying opportunities for collaboration and partnership.
26:04: Next I would like to introduce you to Dr. Jordon Lake. Dr. Lake is the associate professor of medicine at University of Texas. She completed both medical school and internal medicine residency at Bailor College of Medicine in Houston, Texas. followed by infectious disease fellowship and master of science in clinical research degree program at UCLA. Dr. Lake's outpatient practice focuses on HIV infected adults. Her translational research portfolio which is funded by the NIH in industry, focuses on the treatment of metabolic and aging related complications of HIV and anti-retroviral therapy, including optimization of care for HIV infected individuals. Dr. Lake also serves as chair of the NIH multicenter, AIDS cohort study, metabolic working group, and is an active member of the NIH funded AIDS clinical trial group, including service on multiple ACTG, scientific committees, and protocol leadership teams. Dr. Lake will also be assisting us with trial design for HIV and NASH, and identifying collaborative opportunities.
---
27:11: Antonio Migliarese. Thanks Scott. I will be providing a brief update with regards to legal and financial matters today. With regards to legal matters, the company recently began mediation discussions with plaintiffs in the class action and derivative litigations. The company continues to cooperate with regulatory authorities with regards to the ongoing SEC and DOJ investigation. The Amarex dispute continues to be ongoing and at the recommendation of our legal counsel, we are unable to comment beyond that we have obtained our data from Amarex and an independent audit has been performed of the services which Amarex was contracted to perform. We continue ongoing discussions with Samsung to restructure outstanding past due amounts. In the interim, we continue to make monthly payments to Samsung for past due, current and future services. We are doing our best to expeditiously an efficiently resolve the various legal matters facing the company. When or If material events unfold, the company will appropriately update the public
28:13: As Cyrus has described earlier, we have spent a significant amount of time and effort going through planning process. We continue to stay focused on the alliance/spend and with the immediate necessary objectives of the company, identifying areas for the reduction of expenditures and focusing on stretching and making funds last as long as possible. At the end of August, the company's shareholders approved an increase of the authorized shares. This not only allows the company to continue to resolve and address some of our existing and future obligations, but also to have the flexibility to raise capital when non dilutive alternatives are unavailable. Similar to other pre-revenue biotech companies, we require significant capital to support our success. The current board and management are committed to using shares responsibly by raising capital by most advantageous times and terms available at that time. And to use that capital raised to support focused execution of well planned business objectives that we believe will promote maximum value creation.
This concludes the presentation portion of today's webcast.
---
Question and Answer:
29:30 At this time we will continue the question and answer session...
Christina Deleon: Thank you. 1st question: The HIV combination therapy indication has a fast track designation and 2 out of 3 sections have been submitted to the FDA. Have you received any feedback on those pursuant to a rolling review?
Cyrus: Yes, so we took advantage of leronlimab's indication that we have with the FDA as it relates to the BLA for the HIV MDR population; and the FDA responses through that channel, but I mentioned earlier, we are performing an external audit of the collection and documentation of that clinical data and the results from that audit will inform our next steps BLA.
Christina: Thank you: 2) 2 part question: When will you announce the data from the CoVID-Brazil trial? Why were the Brazil trials in Critical and Severe Covid 19 shut down? and is there a plan to restart them?
Scott Kelly: Yeah, so we are working with our collogues in Brazil to determine the proper time to un-blind the data. The trials in Brazil were never put on clinical hold. CytoDyn clinical team decided to pause the Covid 19 trials in Brazil. As the DSMC had a scheduled predetermined date to evaluate safety with in a few weeks. The DSMC met on April 1, 2022 and evaluate the safety portion only of the trial, not the efficacy portion. Their recommendation was to continue the trial with on going monitoring and interim analysis according to the trial protocol. As we stated previously, we would continue to analyze the dynamics of the Covid 19 landscape as it unfolds with a particular emphasis on the critical Covid 19 population. We have been in close contact with our collogues in Brazil and they do not believe at this time, there is enough hospitalized patients in the severe and critical population to recommend continuation with the trials at this time.
31:47: Christina: Next question 3) Why weren't our oncology trial patients tracked beyond the date of their original breakthrough designation submission as that would have allowed us to submit a follow up submission based on the FDA's feedback?
Scott Kelly: So the patient's that remain on leronlimab continued to be followed, but as we stated previously, we don't think that it was enough of an adequate sample size to support a break through designation.
32:17: Christina: 4) On Clinicaltrials.gov, various trials of CytoDyn are mentioned with final completion data before today's webcast. So CytoDyn should inform its shareholders regarding those results of those trials. One of these trials is the Phase 3 trial in which leronlimab is prescribed as single agent therapy, using 3 different dosages in 556 persons with HIV. But more trials of CytoDyn are mentioned. Please inform us.
Scott Kelly: Regarding ClinicalTrials.gov, we are following our regulatory obligation to update ClinicalTrials.gov. Now that monotherapy trial that you are referring to, is not a pivotal trial, it was used to support really the safety of CD02, so we have announced previously the results of the trials that have been completed.
33:10 Christina: 5) What is the status of any law suit with Amarex if there is one?
Cyrus: So, by the advisement of external counsel, we don't comment on those legal matters.
Christina: 6) Could you explain what you discovered about leronlimab and adverse side effects? I was under the impression that over the last few years and all of the studies were Covid, mTNBC, NASH, and HIV, that one of the great advantages of leronlimab, it had an excellent record of very few side effects?
33:59: Cyrus: So when we look at the Adverse Event Profile of Leronlimab on a trial by trial basis, the therapy appears to be well tolerated. And as part of the ongoing work to lift the clinical hold, we are completing an aggregated safety analysis across all of the trials to determine if there is a polled safety signal.
34:19: Christina: 7) How does Patterson's recent patent for CCR5 blocking in long covid 19 affect our efforts on that front and are we still applying for that NIH grant for long covid 19 research?
Cyrus: We have given our redefined Clinical developments focus which does not include Covid treatment in any setting, We don't see this as a concern to our business. Additionally, we do have other Covid related IPs that would protect leronlimab if we were to choose to do anything in that space in the near term. With regard to the NIH grant, our priority really is to complete our submission of all of our documentation for lifting the clinical hold before we would pursue any NIH opportunities for Covid.
Christina: 8) How long does the FDA warning header have to be on the website?
Cyrus: So as mentioned earlier, we completed the Warning Closeout process and the Header is no longer on the website for at least a couple of days.
35:39: Christina: 9) Is the CytoDyn board and management just as open to a buy out as they are to a Partnership?
Cyrus: Shares of the company, we are committed to maximizing shareholder value, right?, so we would consider a buy out offer against a reasonable future valuation that we could expect, and ultimately an acquisition would have to approved by the shareholders anyway. So, I'll leave it at that.
36:08: Christina: 10); Is the board happy with the company progress in their fiscally announced goal to streamline, organize and re-establish confidence with outside agencies?
Tanya: Yes, the board is pleased with the company's progress in rehabilitating its reputation with its key stake holders. That said, we are aware that reputations are built on a foundation of knowledge and communications, but also on actions that are consistent with the communicated principles. One key to cutting through barriers that might impede an organizations effort to re-establish confidence is senior leadership who are committed to the communicated ideals. While we hired him, we believe that Dr. Cyrus Arman shared the boards commitment to a strong corporate ethos. Throughout the first several months of his tenure, we have been pleased to witness Dr. Arman employ an unwavering commitment to strong and responsible governance practices. I would say also, that As an athlete, I know that true strength comes with time under tension, and to this end, we look forward to continue to act in accordance with our stated principles, to further increase stake holder confidence.
Christina: Next Question 11) Please provide an update on the Glioblastoma indication.
Scott Kelly: Realize that there are certain Solid Tumors such as GBM and pancreatic cancer, that remain under study by the drug development community and we will work our KOL to determine the appropriate path forward in those indications.
Christina: Final Question: When will leronlimab be available for State or Federal Right To Try or Standard Access and Compassionate use?
Scott Kelly: I'll take that as well, so, this is something, we are very proud of our efforts in RTT applications and Compassion Use. That being said, we have been just absolutely over whelmed with requests domestically and internationally, we feel it is best for patients and our shareholders at this time, to focus on the approval of leronlimab before we resume any other potential opportunities. Cyrus would you like to provide closing remarks?
Cyrus: I'd like to conclude by reiterating what I said earlier, that the future of the company is bright and that I along with the other key stake holders are committed to seeing leronlimab through to success, to helping patients and to generate financial returns for all our shareholders. Thank you.

I want alot of opinions to decide so iam debating between getting into mechanical engineering or computer science...
My goal : is to find good paying career ( if i got stuck here) with opportunity to get out from Egypt
So i have some questions:
1- حاسبات ومعلومات صعبة كدراسة في المجمل ( انا عارف أن ده سؤال نسبي ) ؟
2-ناس قالتلي أن شهادة هندسة احسن عموما سواء هتشغل او هتسافر برة هل ده صحيح؟
٣- دلوقتي اي حد يقدر يخش مجال السوفت وير فاخد شهادة حاسبات ولا اخش هندسة ميكانيكا واتعلم مع نفسي واستكشف لو حبيت انقل للسوفت وير ( وامسك العصاية من النص) رغم ان الموضوع هيكون اصعب لو بعمل كدة وانا في هندسة ؟
٤- ناس قالتلي ان في هندسة ميكانيكا التغيرات في المجال ابطأ واقل عموما من السوفت وير فالبتالي مش هتحتاج تتعلم حاجة جديدة كل ٣ سنين مثلا
٥ - اني احسن قسم في حاسبات في رايك من دول والي يتيح خيارات اكتر :

• computer science
  
• information system
  
• scientific computing
  
• information technology
  

٦- هل مجال السوفت وير عموما تريند وهيقل عدد الوظايف بعد X سنة ولا مكمل لكتير فشخ قدام ؟
٧- سواء مجالات شغل ميكانيكا او السوفت وير ايه الي بيئة العمل بتاعته احسن؟

• انا عايز بردو نصايحكم عموما لاني مش عارف اقرر ومحتار ( عندي اهتمامات في المجالين )

What is currently taking place is becoming more and more apparent. In the Bio-Pharmaceutical space we are in, competition abounds. And yes, it is a game. A game with no rules. The deeper your pockets extend, the more ammunition you have with which to crush, squash and hammer your enemies. Your inferiority is of no consequence, in fact, it is meaningless. With a little payment of a so called "fee", you're back in the game and its off to the races for you. You don't need to be superior whatsoever; you only need sufficient dough to fill the pockets of your proxies and collaborators; those who work your atypical game for you, in your stead, in your place, for your benefit, so that, in the end, you may remain, afloat, as the last one standing, leaving the general public with no choice but your inferior solution. Just so long as you remain the one standing. Even though you refuse to play by the rules. You don't believe in karma? Why don't you try to beat us by sticking to the rules? By producing a superior product? Too difficult is it? But you are Big Pharma, shouldn't you be able to beat us at the game you are supposedly best at? After all, we are just a measly nobody start-up, while you have invested everything it takes to develop a better business, and a better product. So why do you need to step so low, why can't you live up to your grandness? Oh, you really are not that grand are you? You mean, you really aren't who you claim to be, only your deep pockets make you believe you are the one and only? You need proxies to do your dirty work? Apparently, these are the new rules.
Yes, competition abounds between the Bio-Pharmaceuticals, and some of the players are huge to say the least. However, the games, the matches, the competitions are not arranged by company size. It is not the big vs. the big, nor is it the small vs. the small, rather it is indication on indication. So, for example, it is drugs for breast cancer vs. drugs for breast cancer. It is drugs for HIV vs. drugs for HIV. So this means, it could be Big Pharma vs. Small Pharma on same indication. If one analyzes Leronlimab as a CCR5 blocker, and the disease list which are in CytoDyn's current pipeline and indications, it becomes apparent that CytoDyn is Gilead's number one antagonist or foe. Gilead shares 2 large indications with CytoDyn, HIV and mTNBC. Therefore CytoDyn lie smack dab in the cross hairs of Gilead's sniper rifle. And that is Gilead's modus operandi, sniper like.
In the HIV arena, Gilead dominates with Descovy, Biktarvy & Truvada, yet CytoDyn has superior medication, Leronlimab, which, to this day, unsurprisingly, remains unapproved. Gilead insured this outcome using their proxy Amarex. With what these drugs produce for Gilead, they have no need of Leronlimab, but an approval for Leronlimab would devestate all the income these drugs produce for Gilead within months.
In the mTNBC arena, Gilead has the go to drug Trodelvy, yet CytoDyn has a superior medication which was shut down from advancing to Break Through Designation despite its then equivalent overall survivability and then equivalent Progression free survival and additional effectiveness in eradicating metastasis in general, but especially the metastasis found in the brain. If measured today, Leronlimab would exceed Trodelvy by 150%. Gilead paid $21 billion for Trodelvy and have not even recapped not even $1 billion as of time of this writing. A Leronlimab approval would put an end to any further Trodelvy income for Gilead. No wonder CytoDyn is in their cross hairs.
In Covid19, there is Pfizer and Moderna with their Covid 19 vaccines, which have failed, yet remain on as standard of care, while Leronlimab, CytoDyn's drug which saves dying patients from the brinks of death, easing them back to health, sits on the shelves on deep freeze.
Pfizer owns a drug quite similar to Leronlimab, but also quite different. Yes, both drugs are a CCR5 blockade, but the manner in which CCR5 is blocked is vastly different in the two drugs. The effects of this difference are revealed in the effectiveness of the drugs. Pfizer's drug, Maraviroc, also a CCR5 blockade, has been FDA approved to treat HIV, yet Leronlimab, being a humanized monoclonal antibody which binds to CCR5 also blocks HIV from entering the CD4 lymphocyte, but does it better than Maraviroc with over 81% efficacy and zero side effects, while Maraviroc has a black box warning and less efficacy. With Leronlimab approval, Maraviroc becomes a bygone.
Pfizer recently indicated they were going to pursue the NASH indication. Recently CytoDyn presented their results at the annual liver conference in London. Soon after that presentation, Pfizer said they no longer wish to pursue their NASH indication trials. Did Pfizer realize what they were up against?
CytoDyn has CCR5 G Protein binding humanized monoclonal antibody Leronlimab which can treat a vast number of indications and treat them well, with high rates of success and zero adverse side effects. Leronlimab also has zero drug / drug interactions. Leronlimab may be combined with a vast variety of drugs in a combination therapy or adjuvant therapy manner and Leronlimab as a CCR5 G Protein blockade augmenta and improvea the functionality of the drug it is combined with. As such, Leronlimab has been set up by former Nader regime, to be partnered with and by a great variety of Pharmaceuticals in an effort to increase the capacity, the functioning and effectiveness of the existing drugs.
The situation CytoDyn now finds itself in unfortunately is a necessary evil. It was created by Nader Poorhassan who developed Leronlimab first for HIV and by time of his leaving had developed 32 indications for the drug. These indications are worth billions of dollars behind each of them and Leronlimab can be used either in monotherapy or combination, adjuvant therapy for any of them. Leronlimab needs no other drug, but many a drug needs Leronlimab. Big Pharma has definitively noticed the drug, (and CytoDyn is targeted for it), and Big Pharma has seen the advantages and capacity of the combined use of this drug along with their own drugs as an ideal solution to the progression and propagation of their drug in the treatment of their indication.
The CytoDyn Board of Directors has repeatedly stated on many an occassion that CytoDyn is in talks on potential partnership agreements. Many times, the words NDA have been spoken. It is clear, that Leronlimab is sought after. It is with Leronlimab, that a cure for HIV is being researched by Dr. Jonah Sacha at OHSU and funded by the NIH. It is with Leronlimab, that a study by MD Anderson, on its function with Dostarlimab, PD-1 blocker on its effects in combination against mTNBC. It is with Leronlimab, that its effect on Alzheimer's is being studied in a British University. Leronlimab's effectiveness on Long Haulers has also been already studied at UCLA by Dr. Otto Yang and a Phase 3 study awaits partnership. Leronlimab's effectiveness on NASH has been shown to the world by Dr. Mazen Noureddin at 2022 EASL, Liver Congress, and talks are in session to bring this indication in partnership into reality. Leronlimab's effectiveness in mTNBC is extraordinary and further research is currently underway at MD Anderson Cancer Research which may revolutionize current treatment methods.
It is out of these talks that a Prime Partnership shall emerge. On first mention of the reality of this Prime Partnership, all of Gilead's proxies immediately collapse to their knees, no prone, flat on their faces. CytoDyn's main foe, immediately decides to abandon ship, to call off the mission, to immediately abandon the fight, essentially, to surrender. In one full swoop, the shorts lose it all, and many times over, they cover once, and cover for all, but, in the end they will have lost big. Lo and Behold, they shall find themselves covering at $15 when their original short was at $0.50. When this Prime Partnership is made with CytoDyn, Gilead immediately departs from the game, with their head down, slumps over crawling away from the fight in defeat. Gilead instructs its proxies to give up, to close up shop. The time has come to harrass someone else and to leave CytoDyn alone, because, they will have lost the fight against CytoDyn and they will have lost their own plight to gain Leronlimab for themselves.
All of Gilead's proxies close up shop. ALL of them. None remain. The bashers disappear. The fake law suits dissappear. The shorts disappear. The fake media pieces disappear. The fake DSMC guidance disappears. The fake hit letters disappear. Amarex disappears. etc... All of them go bye bye, when the Prime Partnership is disclosed.
How shall this Prime Partnership come about? How shall it be structured? First off, this Partnership shall boast leadership. Cyrus Arman himself is a leader and understands leadership. The structuring of the deal shall be made by a leader to the advantage of the company he leads. He shall learn of all the advantages of the companies wishing to partner with CytoDyn for the combination use of Leronlimab with their drug, and he will ensure the use of their resources along with sufficient cash influx in exchange for appropriate percentage of gross proceeds of sales. Cyrus is planning to grow CytoDyn vastly, but changes at CytoDyn may become necessary to accomodate becoming the huge conglomerate CytoDyn is destined to become. Cyrus is currently President, but slated to become CEO by December if not sooner. He is charged with increasing share price, and charged with creating partnerships. To that end, I ask that in 6 months, are any changes at CytoDyn currently necessary?
Question, how many partnerships will CytoDyn be in by December 2022? Shall Cyrus become CEO prior to December? My answers to these questions are at least 2 partnerships and Yes, he will become CEO sooner than December. If Cyrus lives up to all he is purported to be, then Yes, he will be CEO prior to December. Partnerships have already been in the works and have been in the making. Cyrus just has to ready CytoDyn to become partner ready. Cyrus needs to position CytoDyn very positively in the green in all of the partnerships he structures. So positively, that CytoDyn can stand strong on solid ground and with stout legs, stable, unwavering, unshakable in the midst of the eventual onslaught which CytoDyn shall always be a part of as being in Bio-Pharmaceuticals. CytoDyn shall grow massive under Cyrus' lead and his governance and he shall show us by what means he shall accomplish his goals. CytoDyn to become CytoDynasty; CytoDyn to become solid as a rock, unshakable, unmovable, stable, rock solid. Proxies dissolved. Enemies afar.
CytoDyn shareholders, we await the news of the 1st Partnership. We await the news of this Prime Partnership that will cause Gilead to pack up shop and scatter. The Partnership that will cause their proxies to stand down, to cover and to exit. This Prime Partnership has to take place first, before, Gilead stands down. Under the terms of this Prime Partnership, authored and structured by Cyrus, Gilead shall find itself lacking the deep reserves to continue to fund their proxies to overcome the new CytoDyn powerhouse under strategic leadership. This Prime Partnership shall be sufficient to cause Gilead to drop their war on CytoDyn and to look elsewhere to pick a fight, or to ready themselves for another future battle for the sought after molecule once they again ready themselves. This Prime Partnership shall give CytoDyn its first capacity to market Leronlimab for the indication. With Gilead out of the way, the roads shall be paved smooth and clean, and it then, shall be only the beginning of many a different avenues CytoDyn shall travel to bring Leronlimab to the ones in need. Mankind shall see Leronlimab, uninterrupted, and it shall be achieved as such, in a broad and diversified manner. Collusionist Gilead shall find itself at war against itself, against acts it committed unlawfully against humanity, by fraud, by deceit, against its foes, against the FDA and against CytoDyn. Gilead shall have its hands tied and have other things to do other than worry about stealing Leronlimab from CytoDyn. But when Gilead emerges out of its war to save itself which it incurred upon itself fully due to its own misdeeds, CytoDyn again shall see them rear their ugly head again, but it won't amount to nearly as much as they have already delivered to us for CytoDyn shall be much greater and more powerful, fully able to deal with the likes of Gilead, come that day, many years ahead.
Who is going to hold back Gilead and their proxies? Who is going to be able to communicate to these entities that there is no longer any point on continuing their daily attacks on CytoDyn? Who will it be that will give CytoDyn the initial capacity to begin its future build viai multi-partnership deals on combination therapy use of Leronlimab? Who shows up and starts batting for CytoDyn?

يبحث العديد من المستخدمين تحميل okanime للكمبيوتر وهو تطبيق خاص بـ محبي ” الانمي” ومشاهدة الرسوم المتحركة وهو تطبيق خاص بأجهزة الاندرويد من تطوير ستوديو 9jiii9il 20 وهو من أفضل التطبيقات في مجال ترجمة المحتوى الخاص بالانمي الموجودة على الساحة فيما يتعلق بهذا النوع من الأفلام والبرامج.

تطبيق Ok anime للاندرويد:

https://parnamg.info/okanime/
يوفر تطبيق أوك أنمي قائمة كبيرة ومتنوعة لأشهر مسلسلات الانمي، وقد استطاع التطبيق أن يحقق نجاحاً كبيرا وحصد تقييماً عالياً 4.5 من أصل خمس نجوم على متجر جوجل بلاي جذب جمهور عالم الانمي في الدول العربية من كل مكان وخاصة محبي الرسوم المتحركة والمانجا اليابانية وذلك لأنهم يجدون صعوبة كبيرة في الحصول عليها مترجمة، ولكن تطبيق Ok anime يوفرها لهم مترجمة وجاهزة من خلال مكان واحد.
يعد تحميل okanime للكمبيوتر من أفضل مواقع الانمي على الانترنت وتقدم للمستخدم فرصة الاستمتاع بأجمل أفلام الرسوم المتحركة التي يحبها الكبار والصغار، فهو تطبيق متخصص للانمي الياباني خصوصاً والتي تطرح الكثير من المشاكل وحلولها من خلال قصة مميزة ومشوقة اعتاد عليها الجمهور الياباني ووصلت للعرب الذين أعجبوا بهذا النوع من القصص، مثل الرسوم الأشهر في العالم ” كونان”.
كما يقدم تحميل okanime للكمبيوتر قصص الرسوم الكاريكاتورية “المانجا” المترجمة والتي تقدم أيضاً أجمل القصص وأكثرها تشويقاً مثل هجوم العمالقة الذي حقق نجاحاً كبيراً في العالم العربي.

خصائص تطبيق Ok anime للاندرويد:

يتضمن تحميل okanime للكمبيوتر العديد من الخصائص التي جعلته مميزاً ووسيلة موثوقة لتسلية الأطفال ومتابعتهم لرسومهم المتحرك المفضل بكل سهولة ودون أي إعلانات مزعجة أو مخيفة أو غير أخلاقية، فالتطبيق لا يزال خالي من الإعلانات المنبثقة.
ويتيح لك التطبيق تنزيل وحفظ أي مسلسل أو فيلم على هاتفك من أجل مشاهدته دون اتصال سواء في طريق السفر أو أوقات الفراغ، وهو ممتاز لعشاق الانمي الذين يفضلون مشاهدة الرسوم المتحركة طيلة الوقت وفي كل مكان، تحميل okanime للكمبيوتر ويهربون من مشاهدتها عبر التلفاز بسبب كثرة الإعلانات خاصة في هذا الوقت من الموسم الرمضاني.
تحميل okanime للكمبيوتر يعني أن كل أعمال الانمي والرسوم المتحركة الياباني بين يديك من خلال هاتفك، فهو يقدم لك أفضل مكتبة أفلام وأعمال درامية بكل أنواعها، تحميل okanime للكمبيوتر إضافة إلى إمكانية استخدام خاصية ” مكتبة المفضلات” والتي تتيح لك إضافة كل ما ترغب بمشاهدته في وقت لاحق وحفظها في حسابك للرجوع إليها بأي وقت.
كما يتيح لك معرفة ترتيب الأفلام أو المسلسلات بحسب الأحرف الأبجدية أو تاريخ إصدارها أو حسب درجة تقييمها من المشاهدين فيمكنك اختيار التصنيف المفضل والأسهل لك للوصول إلى ما تبحث عنه.

مميزات تطبيق okanime للاندرويد :

يتضمن تحميل okanime للكمبيوتر العديد من المميزات التي تجعله تطبيقاً أساسياً في هاتف كل شخص يفضل الرسوم المتحركة والانمي مثل أنه تطبيق مجاني تماما ولا يتطلب أي اشتراك مدفوع، كما أنه يوفر سلاسل الرسوم المتحركة الكاملة والحلقات كاملة.

• يتضمن تحميل okanime للكمبيوتر أكثر من ألفين انمي أفلام ورسوم متحركة.
• يتم تحديث الحلقات بشكل يومي وإضافة كل جديد في عالم الرسوم المتحركة.
• يوفر العديد من الخوادم للمشاهدة وكلها خوادم قوية ولا يتعرض المشاهد للتقطيع.
• يقدم العديد من خيارات العرض والتنزيل بأعلى جودة ودقة.
• يمكن للمستخدم التحكم بدرجة الجودة المناسبة للإنترنت
• يتيح لك إضافة الترجمة إلى الرسوم المتحركة كما ترغب.
• يمكن تنزيل تحميل okanime للكمبيوتر أوك انمي على نظام الايفون دون الحاجة لكسر حماية الهاتف.

إضافة إلى أن تحميل okanime للكمبيوتر يوفر لك الكثير من التفاصيل حول محتوى التطبيقات، ويوفر تصنيفاً قائماً على العمر ويجعل الحلقات متناسبة مع الأعمار ويمكن للشخص أن يستفيد من قدرته على التحكم في واجهة التطبيق وترتيبه كما يحب، ويحدد موقع العناصر التي يبحث عنها ببضع نقرات.
يتوافق تحميل okanime للكمبيوتر مع مختلف أنظم التشغيل إلى جانب الاندرويد يمكنه أن يعمل على إصدارات الـ iOS دون أي مشاكل، والمستخدم لا يضطر لإنشاء حساب جديد.

اقرأ ايضاً:

1. تحميل برنامج bein match للاندرويد اخر اصدار
2. تحميل تطبيق البنك الاسلامي الاردني للايفون برابط مباشر
3. تنزيل برنامج CapCut مهكر للأندرويد

7 خطوات لجعل ويندوز 10 اسرع

منذ أن بدأت العمل مع أجهزة الكمبيوتر ، كان السؤال الأول الذي يطرح علي كثيرًا هو “كيف يمكنني جعل جهاز الكمبيوتر الخاص بي يعمل بشكل أسرع؟” هذا هو أساسًا ما يتعامل معه فني إصلاح الكمبيوتر المحلي كل يوم. عادة ما يكسبون قدرًا كبيرًا من المال من خلال القيام بذلك. إذا كان جهاز الكمبيوتر الخاص بك يعمل بسرعة ، فلن تحتاج إلى إنفاق المال للحصول على مصلح كمبيوتر عين نفسه لإصلاحه لك. كل ما عليك فعله هو معرفة مكان البحث عن الأدوات التي يستخدمها المحترفون. هذا المقال التعليمي من موقع بايتات مخصص للأشخاص العاديين الذين لا يعرفون شيئًا عن أجهزة الكمبيوتر ولكنهم يريدون تنظيف أجهزة الكمبيوتر التي تعمل بنظام Windows وجعلها تعمل بشكل أسرع فلذلك سنعرض عليك 7 خطوات لجعل ويندوز 10 اسرع ، سنشرح خطوة بخطوة مع كل خطوة سأقوم بشرح ما يمكنك فعله لتجعل جهاز الكمبيوتر الخاص بك أسرع .

1. إلغاء تثبيت التطبيقات غير المرغوب فيها

📷
تحقق من لوحة التحكم > البرامج > البرامج والميزات وامسح أي شيء لا تحتاجه. تلك اللعبة القديمة التي لم تلعبها منذ عامين ، تطبيق قمت بتنزيله واستخدمته مرة واحدة ، أي شيء لم تعد تستخدمه بعد الآن. لكن من المهم توخي الحذر لأن إزالة البرنامج الخاطئ يمكن أن يسبب لك مشاكل . عليك فقط حذف ما أنت متأكد أنك لم تعد بحاجة إليه. إذا لم تكن متأكدًا بنسبة 100٪ بشأن حذف أحد التطبيقات ، فاتركه.

2. قم بعمل بحث عن البرامج الضارة

📷
غالبًا ما تكون البرامج الضارة هي السبب الرئيسي لمشاكل بطىء السرعة في Windows. أستخدم ثلاث أدوات رئيسية للتخلص من البرامج الضارة. تعد Malwarebytes و Spybot و Microsoft Security مهمة. كل هذه الأدوات مجانية للمستخدمين وتقوم هذه البرامج بعمل رائع في العثور على أي برامج ضارة على جهاز الكمبيوتر الخاص بك. استخدم Malwarebytes و Spybot وقم بعمل سكان وبعد الانتهاء احذف البرامج اذا كنت لا تريدها . ثم قم بتثبيت Microsoft Security Essentials كاضافة لتجنب الحصول على برامج التجسس في المستقبل .
3. ابحث عن الفيروسات
📷
إذا كان الكمبيوتر لديك يحتوي بالفعل على برامج موثوقة لمكافحة الفيروسات مدفوعة ، مثل Symantec أو McAfee أو Kaspersky ، فتأكد من تفعيلها وتحديثها ، ثم قم بعمل فحصًا كاملاً . إذا لم يكن لديك ، فقم بتثبيت نسخة مجانية من AVG Antivirus واستخدمها للفحص والحماية . AVG مجاني. على الرغم من أنني أعتقد أنه يقوم بتثبيت العديد من التطبيقات على جهاز الكمبيوتر الخاص بك ، إلا أنه يقوم بعمل أفضل من أي من برامج مكافحة الفيروسات المجانية الاخرى .

4. قم بإزالة التطبيقات والأدوات المساعدة التي تبدأ تلقائيًا

📷
يحتوي كل برنامج تقريبًا تقوم بتثبيته هذه الأيام على مكون يحب تشغيله في الخلفية. على سبيل المثال ، يحتوي iTunes على حوالي 5 وظائف يتم تحميلها عند تثبيتها على Windows. تعمل هذه الخدمات باستمرار وتستهلك موارد قيمة ، مما يؤدي إلى مشاكل في السرعة. على الرغم من أنه يمكنك استخدام أدوات Windows الاساسية مثل اداة MSCONFIG لإدارة المهام قيد التشغيل ، إلا أنني أحب تنزيل AutoRuns واستخدامه بدلاً من ذلك. تمنحك هذه الأداة المفيدة شاشة واحدة لإدارة كل شيء يتم تشغيله تلقائيًا. هناك العديد من الأشياء المعقدة التي يمكنك إدارتها في AutoRuns . سنعرض عليكم بعض ميزات البرنامج التي يجب عليك تفقدها .
Services – ادخل على قائمة servives وقم بإزالة أي برامج لم تعد تستخدمها. قد تكون بعض الوظائف مرتبطة بالطابعة القديمة أو الهاتف الذي تستخدمه. حدد أي شيء تعتقد أنك لم تعد بحاجة إليه. ومع ذلك ، كن حذرا لا تفعل أي شيء إذا كنت غير متأكد 100%.
Scheduled Tasks – تعرض علامة التبويب هذه الأحداث المجدولة للتشغيل في أوقات محددة. قد يكون مليئًا بالأدوات التي تتحقق من تحديثات البرامج.
Internet Explorer – استخدم علامة التبويب هذه فقط إذا كنت تستخدم Internet Explorer لتصفح الويب. يمكنك استخدامه لإزالة جميع المكونات الإضافية من IE

5. تنظيف القرص الصلب الخاص بك

📷
حان الوقت للتخلص من الملفات غير المرغوب فيها التي تبطىء القرص الصلب . لهذا يجب عليك أن تستخدم برنامج CCleaner. سيبحث CCleaner في الأقراص الثابتة عن ملفات السجل والملفات المؤقتة والملفات غير المرغوب فيها . تحتوي الأداة أيضًا على ميزة تنظيف السجل التي يمكنك استخدامها كخيار .

6. الغاء تجزئة القرص الصلب الخاص بك

​
يجب تنظيم الهارد لديك بحيث يمكنك العثور على البيانات بسهولة. يؤدي إلغاء تجزئة الأقراص الثابتة إلى تحسين الأقراص للوصول بشكل أسرع. تأتي جميع إصدارات Windows مع أداة مساعدة لإلغاء تجزئة القرص. إذا كنت تريد برنامج آخر ، فإن Piriform (نفس شركة CCleaner) لديه برنامج جميل اسمه Defraggler.
7- تغيير خيارات الأداء
إذا كنت لا تحب مظهر Windows ، فيمكنك تغيير بعض الإعدادات لتعديلها للحصول على أداء أفضل .انتقل إلى لوحة التحكم> النظام والأمان> النظام> إعدادات النظام المتقدمة> خيارات متقدمة ، وحدد الإعدادات .. في منطقة الأداء. من شاشة خيارات الأداء ، يمكنك تحديد “ضبط للحصول على أفضل أداء” للحصول على أقصى أداء ، يمكنك اختيار تخصيص والنقر فقط على النوافذ التي تريدها.
من خلال هذه الخطوات السبع ، ستتمكن من الاستمتاع بجهاز كمبيوتر سريع دون الذهاب لفني صيانة وبدون تعقيدات
هل استفدت من هذا المقال ؟
شاركنا تجربتك في التعليقات.

كود خصم نون الامارات برومو كوبون خصومات وعروض اليوم 2022
كود خصم نون الامارات استخدم كود خصم نون الإمارات 2022 لإجراء عملية الشراء، حيث يرغب جميع العملاء في الحصول على جودة عالية بأقل سعر ممكن.
ويسمح لك متجر نون بتحقيق المعادلة الصعبة من خلال شراء جميع احتياجاتك الشهرية من أفضل العلامات التجارية في جميع أنحاء العالم بأقل سعر ممكن باستخدام رمز قسيمة نون.
كود خصم نون الامارات OL26
كوبون خصم نون الامارات OL26
كود خصم السعودية SH6
كوبون خصم نون مصر CK59

افضل كود خصم نون الامارات

ما عليك سوى نسخ رمز قسيمة خصم نون وإدخاله عند الدفع للحصول على خصم 15٪ على مجموعة متنوعة من الضروريات مثل الملابس، والأجهزة المنزلية، ومستلزمات التجميل، والصحة، والرياضة، والأدوات الخارجية، ومستلزمات حديثي الولادة والرضع، والمزيد.

متجر نون الامارات كود خصم نون الامارات

بعد أن شهد منافسة شرسة بين متاجر الإلكترونيات حول العالم، وخاصة متاجر البيع بالتجزئة لمختلف المنتجات مثل أمازون وجوميا، قرر رجل الأعمال الإماراتي محمد العبار إنشاء متجر نون الإلكتروني باستثمارات إجمالية قدرها مليار دولار أمريكي مع مجموعة من مستثمرون بقيادة شركة الشايع الكويتية وصندوق الاستثمارات العامة السعودي ومستثمرون آخرون.
لأن الصندوق السعودي للاستثمار هو المساهم الرئيسي في نون ستور، فإن حصته في المتجر هي 50٪، في حين أن الـ50٪ الباقية يتقاسمها رجل الأعمال محمد العبار وشركة الشايع الكويتية.
📷كود خصم نون الامارات
لكنهم جميعًا كانوا يعملون على قدم وساق منذ افتتاح المتجر لجعله واجهة رائعة لمبيعات التجزئة في مختلف البلدان العربية، والتي نتج عنها تنوع زيارات المتجر بين 15 و 20 مليونًا شهريًا بمرور الوقت، ويتزايد العدد يومًا بعد يوم مع زيادة تقديم المتجر لخدمات جيدة لجميع عملائه.

هل كود خصم نون الامارات مجاني في الإمارات؟

استمتع بأحدث صفقات أكواد خصم نون 2022 السريعة، بما في ذلك خصم 10٪ عند الشراء باستخدام "فيزا" أو خصم 15٪ عند الدفع ببنك الإمارات الوطني أو فيزا البنك الإسلامي، ووفر أكثر مع نون اليوم عن طريق التسوق مع بنك ساب والحصول على خصم 20٪.

منتجات نون الامارات

كود خصم نون الامارات ليس من قبيل المصادفة أن نون دخلت السوق الإلكتروني الأبرز في المنطقة في مرحلة مبكرة من تطورها، حيث تشارك منصة نون الإمارات الإلكترونية في عالم التسوق عبر الإنترنت بما يعادل 20 مليون عنصر، وهو حقًا رقم ضخم للغاية.
كود خصم نون الامارات عند زيارة متجر نون الإمارات عبر الإنترنت، سوف تكتشف الأطعمة والأدوات الإلكترونية من جميع الأنواع، بالإضافة إلى الأدوات المنزلية والمطبخ مثل الأثاث والديكورات ومستلزمات الغرف والحدائق والأواني وإلكترونيات الطهي.
بالإضافة إلى الملابس الأنيقة والجاهزة للرجال والنساء والأطفال والمراهقين، تتوفر الكتب والألعاب، وبالنسبة للسيدات، هناك مساحة كاملة لمستحضرات التجميل والعطور، بالإضافة إلى مستلزمات الأمهات والأطفال الجدد، أولئك الذين يهتمون بكل الأشياء التقليدية سوف يكتشفون ما يبحثون عنه في بازار متجر نون الإمارات، باختصار، نون الإمارات تجمع كل ما تحتاجه في حياتك، بغض النظر عن هويتك أو مدى أهميته.

كوبون خصم نون الإمارات

سياسة الكوبونات وعروض الخصم هي سياسة متبعة في جميع الأسواق الإلكترونية، وقد خطت نون الإمارات خطوات كبيرة في هذا المجال من خلال تقديم خصومات وعروض ممتازة كجزء من سعيها الذي لا ينتهي لإسعاد عملائها الكرام، كل ما عليك فعله هو الانتقال إلى موقع متجر نون الإمارات والبحث عن أحدث كوبونات الخصم والصفقات.
حيث أن هناك العديد من الصفقات المتاحة التي ستتيح لك شراء أشياء بأقل من نصف السعر، بالإضافة إلى ذلك، تعلن نون عن خصومات يومية، مثل العروض الخاصة باختتام الدراسة وبداية الدراسة، وكذلك عروض على الألعاب التي تقترب من نصف خصم المنتج، بالإضافة إلى عروض مذهلة على جميع الماركات العالمية وجميع معدات مستحضرات التجميل، مع كوبون خصم نون الإمارات العربية المتحدة، ستتمتع بقوة شرائية أكبر، مما يجعلك المستفيد الأكبر لموقع نون الإمارات.

خيارات الدفع في نون الإمارات العربية المتحدة

بالإضافة إلى بوابة الدفع الإلكترونية الفريدة من Noon Emirates MoneyPay، هناك طرق تقليدية مثل بطاقات الخصم وبطاقات الائتمان، وجميعها وسائل دفع مضمونة وآمنة للعملاء.

سياسة التوصيل في نون الإمارات العربية المتحدة

لا تتجاوز خدمة التوصيل الخاصة بالمنصة نفس اليوم في المدن الرئيسية بدولة الإمارات العربية المتحدة عبر خدمة التوصيل السريع Noon Transport، الميزة الإضافية هي التوصيل المجاني للطلبات التي تزيد عن 100 درهم إماراتي.

ما هي سياسات الإرجاع والاستبدال في موقع نون؟

في المقام الأول، يقدم Noon Store سياسة تبادل واسترداد مباشرة للعملاء، والتي يمكن ذكرها على النحو التالي:
ترحب Noon بتبادلات ومرتجعات البضائع التي تم تسليمها بشكل غير صحيح أو لا تتطابق مع الوصف الموجود على موقع المنتج على الويب.
إذا كانت البضاعة التي حصلت عليها بها أي تلف أو مشكلة في التصنيع.
عندما ترغب في مبادلة وإرجاع عملية شراء دون إبداء سبب، مثل تغيير رأيك في هذا الشأن.
ما هي سياسة الإرجاع والاستبدال للأشياء المشتراة من متجر نون؟
المدة المسموح بها لاستبدال المنتج وإعادته في متجر نون بحد أقصى 7 أيام، يتم حسابها من تاريخ استلام الطلب المرفق بفاتورة شراء المشتري.

هل من الممكن مراقبة طلبي داخل متجر نون؟

كود خصم نون الامارات يحتوي Noon Shop على أداة محددة لتتبع الطلبات تتيح لك تتبع طلبك من وقت مغادرته المتجر حتى استلامه، عبر البريد الإلكتروني أو الرسائل النصية القصيرة أو منصة Noon Store.

هل سيتم إعادة الأموال إلى حسابي بعد اكتمال إجراءات الإرجاع؟

في غضون 7 إلى 14 يومًا من موافقة المتجر على استبدال أو إرجاع العناصر وتلقي اتصال من العميل، يتم إرجاع المبلغ المدفوع إلى رصيد حسابك في متجر نون أو إلى بطاقتك الائتمانية في حالة إجراء معاملة بطاقة الائتمان.

كيف يمكنني التواصل مع خدمة عملاء نون الإمارات؟

لدى متجرNoon العديد من الخيارات للتعامل مع دعم العملاء، والذي يتوفر على مدار 24 ساعة في اليوم، سبعة أيام في الأسبوع، يمكنك الاتصال بهم باستخدام الطرق التالية:
استخدام منصات الشبكات الاجتماعية الخاصة بـ Noon Store للتواصل.
[email protected] هو عنوان البريد الإلكتروني للاتصال.
اتصل بنا مباشرة عبر علامة التبويب "اتصل بنا".
اتصل على 8888-3-800.

ما هي أشهر الماركات الأجنبية المتوفرة في متجر نون؟

Apple: يقدم متجر Noon أحدث الإصدارات من جميع منتجات Apple بمجموعة متنوعة من الألوان والأحجام، بدءًا من الهواتف الذكية وأجهزة الكمبيوتر المحمولة والساعات الذكية إلى أجهزة iPad والأجهزة اللوحية، عندما تشتري عناصر Apple من Noon، يمكنك التأكد من حصولك على منتج Apple أصلي بدون عيوب أو مشاكل.
Nike: يقدم متجر Noon جميع عناصر Nike الأصلية بأسعار مذهلة، بما في ذلك الملابس والأحذية والإكسسوارات، ويدعمها من خلال إصدار كود خصم Noon الفعال على جميع معاملات Nike.
كود خصم نون الامارات Samsung: تقدم Noon جميع منتجات Samsung العملاقة الكورية بسعر تنافسي، بما في ذلك الهواتف الذكية وأجهزة التلفزيون والأجهزة المنزلية وسماعات الرأس وغيرها من المنتجات الأصلية والمضمونة عالية الجودة، كما تقدم كود خصم نون للحصول عليها في سعر معقول.
تيفال: حيث توفر نون جميع عناصر تيفال الأصلية والمطلوبة دائمًا نظرًا لجودتها وأسعارها الاستثنائية، فضلاً عن الخصم المتاح عليها من خلال استخدام كود خصم نون المناسب كود خصم نون الامارات.

CytoDyn is an OTCBQ company has a history dating back to 2011 and it started with the prior CEO, Nader Poorhassan purchasing PRO140. CytoDyn owns the Intellectual Property, (IP) of the PRO140, (Leronlimab) monoclonal antibody molecule. Samsung manufactures Leronlimab for CytoDyn. Leronlimab is a subcutaneous injection dosed weekly in the home or as an IV infusion dosed at hospital or infusion center depending on indication. Leronlimab staunchly binds to the CCR5 cytokine effectively creating a CCR5 blockade lasting approximately a 3-4 week half life. Depending on the indication, it is dosed anywhere between once a week, to once a month, to once every 3 months. Leronlimab blocks 100% of the CCR5 cytokines as measured by Receptor Occupancy Testing and subsequently, the associated Innate inflammatory cascade is thwarted while allowing the Adaptive Immune Response to continue as usual. In HIV, it operates as a Viral Entry Inhibitor. Over 70 HIV patients, (one of whom is Charlie Sheen), have been using Leronlimab already now for over the past 7 years now without any Adverse Side Effects. The indications for this molecule are vast and numerous with the current indications having a value of nearly $330 billion annually.
Some of the indications currently being considered for Leronlimab are: multi-drug resistant HIV, monotherapy HIV, combination therapy HIV, long-acting PrEP HIV all of which worth nearly $10 billion. See Publication in “November 2021, Frontiers” “CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+T Cells Following Treatment with the Anti-CCR5 Antibody Leronlimab”. See also the Publication, “June 2021, Nature Communications” “Antibody based CCR5 blockade protects Macaques from mucosal SHIV transmission”. In February 2018, CytoDyn hit the Primary Endpoint in the Leronlimab + Combination trial for HIV and achieved a p value of 0.0032, however, due to a negligent Clinical Research Organization, (CRO), CytoDyn has yet to complete the Biologics License Application, (BLA). CytoDyn has hired Sidley Austin Attorneys who are currently in arbitration with that CRO and have already obtained the trial data which they kept from us so we could not file the BLA, but that has been recovered. Sidley Austin is in arbitration for the damages against CytoDyn and the patients in the trial on account of the negligence the CRO did on the BLA.
Metastatic Triple Negative Breast Cancer is another indication for CytoDyn’s CCR5 blockade Leronlimab. CytoDyn conservatively values this indication at $50 billion. The global cancer therapy market was valued at $158 billion in 2020. It is expected to witness revenue of $268 billion in 2026. “CCR5, a seven trans-membrane G-protein coupled receptor (GPCR), is normally expressed only in the immune system; however, CCR5 becomes overexpressed in several malignancies and is overexpressed in breast cancer”.
CytoDyn has completed a Phase 1 metastatic triple negative breast cancer trial with 29 patients. 21 out of the 29 patients responded to the Leronlimab treatment as verified by increases in Cancer Associated Macrophage Like (CAML) cells and / or Circulating Tumor Cells (CTC). 21 of 29 patients remained alive at the 12 month point of analysis with only a series of (4) 700mg Leronlimab injections + carboplatin. Had these patients received Standard of Care, they would more than likely have died by the 6-7 months point. In the trial: “Compassionate Use Study of Leronlimab in Breast Cancer”, there was a 570-980% increase in Overall Survivability, (OS). Leronlimab doubled the stand alone Standard of Care: Paclitaxel for PD-L1 BC in Progression Free Survival, (PFS) and Overall Survivability, (OS).
Leronlimab in mTNBC after filing for Break Through Designation, (BTD) for mTNBC, almost became the new standard of care, being 3,600% better than chemotherapy, but was told by the FDA that Trodelvy had won that BTD. Trodelvy has a long list of adverse side effects, where as Leronlimab has no reported severe adverse effects and matched or obtained better results than Trodelvy. Currently, We currently estimate that Leronlimab’s OS exceeds 18 months.
See Publication, “January 2021 Breast Cancer Research” “Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy”. “The efficiency of leronlimab binding to CCR5-positive human breast cancer cells was up to 98%” https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-021-01391-1. “Prevents overexpression of CCR5 which promotes tumor invasion, migration, and metastasis. In the analysis of > 2200 breast cancer patients, > 50% of patient’s tumors were CCR5+. and > 95% of triple-negative breast cancer (TNBC) were CCR5+” (1) https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-021-01391-1.
CytoDyn believes that they will be the premier Oncology Company that decimates the tumor macro environment. Leronlimab prevents tumor angiogenesis by blocking CCR5; it also blocks CCL5 (RANTES), which promotes Vascular Endothelial Growth Factor (VEGF), which would lead to angiogenesis or the formation of the blood supply to support tumor growth. MD Anderson and other top oncology universities are currently studying breakthrough capability of Leronlimab and possible synergistic effects in oncology. See Publication, “April 2021 International Journal Molecular Sciences” “Update on Glioblastoma Biology, Genetics and Current Therapies: Novel Inhibitors of the G Protein – Coupled Receptor CCR5”.
Liver metastatic burden was decreased 59% in leronlimab-treated mice. Lung metastatic burden was decreased 87% in leronlimab-treated mice compared to IgG-treated animals (p=0.012). “Leronlimab reduced lung metastatic burden > 98% at 8 weeks (99.6%). Collectively, these results provide evidence that the CCR5 antagonist leronlimab reduces the formation of lung metastasis in a murine xenograft model.” https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-021-01391- 1.
“CCR5 is over-expressed in breast cancer, gastric adenocarcinoma, prostate cancer, colorectal carcinoma, melanoma, Hodgkin lymphoma, head and neck cancer, gastric cancer, esophageal cancer, pancreatic cancer, acute lymphocytic leukemia, and other tumors.” https://cancerres.aacrjournals.org/content/79/19/4801.
A Basket Trial of 22 different cancers has been completed and as Leronlimab crosses the blood / brain barrier, it has shown significant improvement in brain metastases and even neurologic conditions like Alzheimer’s. CytoDyn is potentially partnering overseas for Multiple Sclerosis and Alzheimer’s disease.
Another Leronlimab indication is Non Alcoholic Steato-Hepatitis or NASH and NAFLD. As hepatocytes contain CCR5, and the cells that produce scar tissue in the liver also contain CCR5, Leronlimab subsequently blocks liver fat production, liver scarring and fibrosis of the liver. 75% fat reduction and 80ms average CT1 drop in fibrosis with double blinded 350mg dosing is a huge decrease in severe NASH patients which is evidence of resolution of fibrosis. 700mg data is complete but not yet unblinded and Top Line Results aren’t out quite yet. CytoDyn is looking for partnership to do a 1,000 patient Phase 3 trial for 700mg NASH trial once the 700mg Top Line Results are out and that can be any day now. CytoDyn values NASH as a $10 billion indication.
Another indication for Leronlimab is SARS-COV2 or Covid 19. CytoDyn holds the patent for CCR5 blockade in corona virus indications and severe inflammation for 40 years. CytoDyn conservatively values Critically Ill Covid and LongHaulers disease at $5 billion. Leronlimab has treated over 80 individuals as eIND patients and more than 200 people in the Philippines under Compassionate Special Purpose. CytoDyn conducted a US Covid 19 trial and would have met the Primary Endpoint, but was forced by the FDA to only give 2 subcutaneous doses over the critical 1 month period when 4 doses should have been given, (one dose every week). Leronlimab has amazing efficacy in trials when dosed weekly. To combat the efficacy, the FDA only allowed 1 weekly dose of Leronlimab for only 2 of the 4 weeks of the Covid-19 Critical Trial which resulted in a near miss in our p value of 0.052.
Leronlimab had shown 81% survival rate in critical Covid patients the first two weeks of the allowed doses. The Data Safety Monitoring Committee, (DSMC) noted no safety issues and yet no halt was done. The trial was recommended to continue, knowing that patients would not get injected for 2 remaining weeks and these patients were allowed to regress with no medicine for the last 2 weeks of their trial period. Some even ended up dying on account of this malfeasance. In addition, the DSMC allowed the unfair pairing and age stratification discrepancy amongst the patients. The older you were with Covid, the more you were likely to die, and a vast majority of the elderly were curiously in the shorted Leronlimab arm, while the placebo arm was full of patients under 50 years of age, yet this was allowed even though FDA commissioner Janet Woodcock famously stated, “People say they want placebo-controlled trials, but I always ask them: 'Would you be willing to die to give a p-value?”. Another bizarre coincidence, was that one of the 3 DSMC members had been a former Gilead employee, a direct competitor of CytoDyn. As a result of the obvious workings of the FDA in collusion with Big Pharma to combat Leronlimab’s efficacy, CytoDyn headed outside of the US to the Philippines and Brazil.
Simultaneous with Covid-19, a 13D uprising was happening within the company. 13D was making manipulative efforts toward investors indicating that they had a plan to see approval; while all the time, they were discounting management as bad on multiple accounts. 13D succeeded in hurting the reputation of the company. For example, every positive announcement of CytoDyn was matched by 13D announcements belittling management’s efforts. To spy on the company, and further hurt CytoDyn’s reputation, a 13D plant, had infiltrated CytoDyn headquarters to “help” the company. Self proclaimed CCR5 expert, Bruce Patterson, MD, took a non-disclosure agreement, NDA with the CytoDyn and later tried to claim the IP for Leronlimab for himself. He tried stating that the patent for leronlimab rightfully belonged to him. Accomplishing nothing during his contracted tenure, he went on Ted Talks and spoke highly of the drug. Friends of Bruce Patterson began to pump the stock, only to somehow know when to sell and short it in a timely response exactly as Citrons short attack began. That was shortly followed by ambulance chasing lawsuits against CytoDyn which were completely fraudulent and which did not amount to anything. After pumping and dumping the stock, 13D plants on message boards started to hound and take over CYDY investor boards like Yahoo Message Board and Reddit. They portrayed themselves as investors who would “finally” see us over the botched BLA they claimed CytoDyn management was 100% responsible for when they knew all along that the CRO purposely botched the BLA in their favor. In the end, 13D did not succeed because they failed to abide by the public by-laws of the company and also failed miserably to file with the SEC properly. Many investors believe this wasn’t an actual attempt, but was rather purposely done to hurt the company for easier acquisition.
While 13D was successfully belittling CytoDyn, Leronlimab had been working exceptionally well in the Philippines, but in right in line with the 13D attempted overtaking, the FDA had timely written a public letter reprimanding CytoDyn for portraying anecdotal evidence as “evidence based medicine”. This led to another perfectly timed short attack which occurred 15 minutes following the release of the FDA letter. In addition, all the good news of the Philippines was outdone by the FDA letter which was also encouraged by the Pilipino ‘YouTube’ doctors who also supported the 13D movement.
CytoDyn moved Covid overseas to Brazil for a trial. The Covid 19 trial is currently on going in Brazil. CytoDyn has improved 18 out of 24 symptoms in Long Covid patients in an exploratory trial. Leronlimab is potentially the answer to 30-50% of Covid survived patients that suffer from Long Covid. CytoDyn is looking for partnership for Long Haulers.
Leronlimab’s potential disruption to Big Pharmaceutical Industry is similar if not bigger than what Amazon was to in disrupting the retail industry. Saving the lives of people or extending their lives is more critical and valuable during these times than the retail industry ever was.
Investors believe that the FDA, Big Pharma, Big Money, Big Media and Dark Money are in cahoots with each other, slow walking CytoDyn’s trials and trying to dim the lights on anything positive about CytoDyn and / or Leronlimab, thereby cornering them into a position needing to partner or to get acquired. Many frivolous lawsuits and a failed 13D take over seem to be coordinated to hurt the stock value to make negotiations better for those trying to partner or acquire the company.
The FDA recently had CytoDyn completely re-vamp their entire website and had them remove anything and everything including previous Press Releases and prior Publications which could potentially be construed as advertising of the drug Leronlimab as safe and / or effective, even though the drug has saved lives; the fact that there’s no reported severe adverse effects, and the drug has been safely used by HIV patients for over the past 7 years. This FDA imposed statue doesn’t help patients, or retail investors, but it does help Big Pharma, and Big Money like hedge funds or BlackRock who own Big Pharma who would profit from shorting the company.
Many long investors are staunchly bullish on Leronlimab and its capacity to effectively treat many indications and believe that despite the massive opposition that CytoDyn has been facing, the truth of the numbers which Leronlimab produces, cannot be disregarded, especially, when so many patient’s health are infinitely improved without any adverse side effects of taking the drug. Long CytoDyn investors believe that the FDA and Big Pharma cannot indefinitely suppress the facts about Leronlimab and that Leronlimab shall be approved on its own merit in short order.
The last 1/3 of the HIV BLA is currently being put together with the audited data that the previous CRO was forced to provide by court injunction as a result of Sidley Austin’s handiwork. The management of CytoDyn is diligently working to assemble this redacted BLA for HIV in short order. The 700mg NASH Topline Data Report shall also be released soon. The mTNBC phase 2 trial continues to run as a Fast Track Designation, but the BTD for mTNBC is no longer being pursued as the FDA is not supporting this since Trodelvy by Gilead took that regardless of its inferiority to Leronlimab.
We feel that once the BLA for HIV is filed and / or the NASH 700mg Top Line is released, the CYDY share price will rise swiftly. In addition, under pressure, CytoDyn terminated the previous CEO Nader Poorhassan and currently, does not have a CEO. The Board of Directors is currently looking for a CEO. The Scientific Board is packed with doctors who feel Leronlimab is the answer on the indications discussed above and for numerous other indications not here in discussed. The Board of Directors is working on keeping the company afloat amidst the negativity and attacks made by the FDA, by Big Pharma and by Big Money. Certainly, it is understood exactly why there is such staunch opposition to CytoDyn and to Leronlimab and that reason is because Leronlimab is so effective at what it does as a CCR5 blockade, while being harmless to the patient. The stakes are enormously huge because the size of these markets are immense, exceeding the range of $200-300 billion.
As of late, there has been tremendous pressure on the stock price. The price has been falling on a day by day basis for months. It has been as high as $9 in 6/2020, but quickly fell from there. The price had held at $3-5 when there was excitement and when 13D had not revealed themselves. Once 13D made their presence known, it has just been a never-ending downhill slide, lower and lower. Currently, CytoDyn trades for $0.25 and every shareholder is under water. Big Money shorts the stock day after day, by over 50% of daily trade volume. There is no relief in sight as these big entities want CytoDyn dead. They want Leronlimab gone. They do not want it as a competitor because they know they cannot overcome it if it were to arise, so their hope is to crush it now and not give it a chance to grow.
The powers that be are very strong, and they are crushing the CYDY share holder base and many are abandoning ship, thereby leaving themselves without a means to make back their losses. However, if Chris Recknor, MD on the Board of Directors indicates that he has all the data he needs to submit the BLA for HIV, CytoDyn sails again. Once he gives the NASH 700mg Topline Data and the data proves out the astounding expectation that liver fat and fibrosis are significantly and truly reduced by leaps and bounds, CytoDyn sails again and rises with the tide. There are other Leronlimab trials coming to a close, for various indications, in the proximal future as well. So it’s now, sort of a race. Will the shorts tank the stock to zero before Recknor makes these announcements, or will it be the other way around?
Chris Recknor already believes that he has all the data necessary to make a prepared BLA for HIV acceptable to the FDA. He also believes the 700mg NASH data is exceedingly superior to even the 350mg data which was itself was exceptional. He just has to continue the audit with the CRO for Pharmaco - Vigilance. Therefore, it is conceivable that the CytoDyn board may be toying with the shorts, as a kind of foreplay to generate a massive short squeeze. They may be purposely permitting the market makers to bring the share price down, penny by penny on a daily basis, when they already possess the overwhelmingly good news in their back pockets, again, to set up a short squeeze; Recknor just may be waiting for confirmation. Big Money unwittingly maintains its shorting position, holding nearly 50,000,000 shares traded short, lowering share price daily, lower and lower with no end in sight, trading short over 50% daily volume, with their only intent to put CytoDyn 6’ under. It seems everyone is against this company, at least that’s what it seems, but the Board of Directors, quite possibly possess something, very big, up its sleeve.
Long shareholders of CYDY believe that a lot of action will happen in the near future. A lot should be unfolding soon. There is a lot of conflict currently because Leronlimab is such a wonderful medication, yet, it is hated by Big Pharma and by Big Money because it works so well and can have a huge deleterious impact on some big name drugs for big money indications & on some big name funds who own the companies which make those drugs for those indications. Therefore, a good solution for both parties is to graft CytoDyn and Leronlimab into the Big Pharma world and for CytoDyn to uplist to the NASDAQ so it may be purchased by Big Money as well. For this to happen, Long time share holders believe that multiple partnerships with various big name pharmaceuticals on their indications would benefit those multiple pharmaceuticals simultaneously. It would also benefit the big money funds who own those partnering with CytoDyn. Another option would be to partner with a larger non-pharmaceutical, such as Samsung who caters to the pharmaceutical industry and then Samsung would assimilate the partnership with CytoDyn with Big Pharma and Big Money thereby enabling which ever Big Money like Black Rock owning Samsung to benefit.
The partnerships won’t happen until the Amarex arbitration is at a minimum, cleared up a bit. That will take an utterance from Dr. Chris Recknor in conjunction with the CRO for Pharmaco – Vigilance, that he will be able to submit a successful BLA for HIV based on the audited data they received from Amarex. In addition, the 700mg NASH data Top Line results need to be revealed and they need to show astounding numbers revealing that Leronlimab obliterates Fat and Fibrosis in the liver, hands down. Lastly, after these things are revealed, then a new CEO may be brought on.
Needless to say, CytoDyn is currently searching for a CEO. With the versatility of Leronlimab, CytoDyn believes that their path forward is to develop multiple Pharmaceutical partnerships made with companies in varied fields, (ranging from HIV, to Oncology to Liver Disease & beyond), to use Leronlimab in combination therapy with their approved drug to augment its effectiveness for their specific indications.
CytoDyn is currently searching for a CEO who has serious connections in the Pharmaceutical Industry. The CEO needs to have a special drive to help people deal with awful diseases such as HIV and Cancer. He would have a deep ambition for, and personal goals of helping humanity with cures for patients with cancer, HIV, and also for treating the numerous maladies which Leronlimab successfully combats by blocking CCR5. The CEO would learn and understand the mechanism of action of Leronlimab and clearly understand the complexity, the versatility, flexibility and extensive usefulness & broadness of the applications which Leronlimab easily addresses.
As such, this CEO would help humanity by delivering Leronlimab to the people through his own, previously established, network of connections. He would bring CytoDyn together with a diverse group of Big Pharmaceutical companies into partnerships to treat a variety of their indications. Through his direction, and using Leronlimab’s versatility, CytoDyn would enter into partnerships with Big Pharmaceuticals on indications that those Big Pharmaceuticals specialize in, helping them to achieve their goals while CytoDyn achieves theirs.
The CEO would be versed in business and medicine. He would understand patent law. He would have published many papers. A great passion of his is to help people fight disease through the use of medicine and health care. He would do this by bringing multiple companies together, (even those who may be rivals with one another), into a sort of “coalition” through CytoDyn with the augmentation of Leronlimab to the current treatment regimen.
Nader Poorhassan had set the stage, but that stage is now closing, marked by his termination. The new CytoDyn marked by partnerships begins with the incoming CEO. CytoDyn is currently in transition.

With the incompetent and dishonest NP gone, the company now has a chance to capitalize on development of Leronlimab. Management appears to be taking the responsible and fiscally cautious path in focusing on partnerships and private and government outside funding for trials. That was the approach the 13D group proposed.
It is now crystal clear that the partnership approach was the responsible approach but probably could not be followed while NP was CEO due to his checkered past. The 13D Webcasts supported that analysis. With NP gone, a big obstacle to partnership and funding has been removed.
Now we will see whether Dr. Patterson, Lalazari and other independent experts in the field were right about the value of Leronlimab. Clearly Management believes they were based on their strenuous efforts to deal with the NP created problems and put them in the rear view mirror.
Good final NASH trial results would provide a nice boost to the company's credibility and likely the share price. Dr. Recknor (who I find credible) believes, based on the analysis to date, that the results will be good. He indicated we would see the final analysis in a couple of weeks (maybe 4/14).
I expect the meta safety analysis of all the trials FDA is looking for to be no problem based on the fact that no safety trial has reared its head in previous years.
Sounds like the Brazil CYDY initiated voluntary hold, based on two critically ill patient deaths which are normal in this population, won't require discontinuance of the Brazil covid trials. The DSMC to review this safety issue is soon and we should get an update in a few weeks or so.
As for the HIV Combo BLA effort, it is no clear to me what CYDY needs from the Amarex data evaluation beyond the meta safety analysis. It is also not clear to me whether Receptor Occupancy test CYDY developed and required for the BLA has been validated yet.
Receptor Occupancy evaluation has been the biggest obstacle to the HIV Combo BLA filing. The Webcast did not address whether their RO test has finally been validated. So it is a potential problem area. At the moment, the best investors can say about it is that current management appears to be responsible and competent and will have what they need to support that HIV Combo BLA filing. Still, it would be nice to have an update on the RO test issue from Management.
The rest of the Covid effort depends on partnership opportunities. With NP gone, the logical move would be to reconnect with Dr. Patterson and see if their was anything they could do with him with respect to a long hauler trial funded by Patterson sources.
TNBC data is good so far but needs more trial data and a partner to fund it according to Management.
The Company has added respectable people to the Board and Scientific Advisory Committee. This is encouraging and likely to improve the chances for partnerships. It indicates that those with scientific expertise believe that the science behind Leronlimab continues to show promise. That was the original reason to invest in CYDY.
SEC and Justice Dept investigations are ongoing. With the company cooperating, I expect action to be taken against NP for his deceptive behavior at some point. I doubt the government wants to hurt shareholders victims of NP's bad behavior.
In sum, the Company has a decent shot at successful Leronlimab development but it will likely take years.

134 million shares left as of the date of the filing. They’re dwindling quickly as the price decreases. 134 million shares at .20 would only raise $26.8 million, which wouldn’t even cover 50% of the total added to Samsung and Fife.
“As of the date of this filing, the Company has approximately 134.0 million shares of common stock unreserved, authorized and available for issuance under its certificate of incorporation, as amended”.
Speaking of shares and dilution, another 63.1 million shares and 45 million warrants are being offered privately via a private stock offering. That’s 108 million of the 134 million remaining. I’m assuming Paulson is conducting the offering. Those shares are a tough sell given the current situation.
“In early April 2022, the Company commenced an offering of up to 61.3 million units, with each unit consisting of one share of common stock and three-quarters of a warrant to purchase one share of common stock”.
Speaking of shares, again, Fife is still owed $40.5 million or so. Multiple times in the 10q states that Fife has waived numerous events of default over the past several months. Accounts payable total $65.9 million as of February 28, 2022, which DOES NOT include the money owed to Fife.
“As of February 28, 2022 and May 31, 2021, the accounts payable balance was $62.4 million and $65.9 million, respectively, with two vendors accounting for 62% and 19% and 72% and 14%, respectively, of the total balance of accounts payable and accrued liabilities”.
Samsung is owed $38.1 million. CYDY claimed they have until July 1st, 2022, to pay the amount despite Samsung sending a letter that CYDY is past due by at least $13.5 million as of December 31st, 2022. CYDY is looking at options for payment, including using shares (which are running low).
“ Management is in ongoing discussions with Samsung regarding potential approaches to resolve these issues, including proposals by both parties of a revised schedule of payments over an extended period of time, and proposals by the Company of satisfaction of a portion of the Company’s payment obligations in equity securities of the Company and postponing or cancelling the manufacturing of additional drug product provided for in the agreements. As of February 28, 2022, the Company had past due balances of approximately $38.1 million due to Samsung which were included in accounts payable as of February 28, 2022”.
Corrective actions by CYDY re most recent FDA letter may still be on the way. Proactiv video with SK correcting NP’s promises?
“The FDA further alleged the video misbrands leronlimab under section 502(f)(1) of the FD&C Act and in violation of section 301(a) of the FD&C Act, as the claims in the video make representations in a promotional context regarding the safety and efficacy of an investigational new drug that has not been approved or authorized by the FDA. The Company is working closely with the FDA to resolve this matter and take the proper corrective actions”.
SEC/DOJ investigation continues. I believe the new part of this section is that certain executives have received subpoenas and may be interviewed by the DOJ/SEC.
“The Company has received subpoenas from the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain Company executives have received subpoenas concerning similar issues and may be interviewed by the DOJ or SEC in the future. The SEC informed the Company that its inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or security”.
One piece of good news from the 10q: DSMC recommended the COVID trial in Brazil continue. CYDY has sent the recommendation to ANVISA to get the trial enrolling again
“April 2022, the DSMB for the Brazilian COVID-19 clinical trials met and recommended that the Brazilian COVID-19 trials, previously paused by the Company, may continue based on the review of the interim patient safety data from the clinical trials. The Company is in the process of providing this information to ANVISA for their subsequent review of the information prior to commencing the enrollment of new patients in the Brazilian trials”.